CONTACT
+91 80 2808 2808
info@biocon.com

News - Posts

Biocon  /  News – Posts

Biocon Academy Conducts its 8th Graduation Day

  • Posted by: BIOCON

Biocon Biologics Concludes Integration of Acquired Biosimilars Business in ~120 countries

  • Posted by: BIOCON

Biocon is neither Evaluating Any Divestment Options for Its APIs Business nor Consulting any Bankers

  • Posted by: BIOCON

Biocon Biologics Recognized as an Asia IP Elite for 2023, IPR Team adjudged as the Team of the Year

  • Posted by: BIOCON

Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe

  • Posted by: BIOCON

Biocon Biologics Receives MHRA, UK Approval for YESAFILI®, Biosimilar Aflibercept

  • Posted by: BIOCON

Biocon Q2FY24 Revenue at Rs 3,620 Cr, Up 52%; Biosimilars Up 97%; Research Services Up 18% EBITDA at Rs 900 Cr, Up 68%; Core EBITDA at Rs 1,100 Cr, Up 35% Net Profit at Rs 126 Cr, Up 168%

  • Posted by: BIOCON

EdelGive and Hurun India recognizes Kiran Mazumdar-Shaw as the Second most generous women philanthropist in India

  • Posted by: BIOCON

Biocon Biologics Announces Divestment of Two Non-Core Branded Formulations – India Business Units

  • Posted by: BIOCON

Biocon Ranked No. 8 Among Science Magazine’s Best Employers in Global Biotech and Pharma Sector

  • Posted by: BIOCON
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>